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Abstract: Lewy body diseases are characterized by the presence of Lewy bodies, alpha-
synuclein(AS)-positive inclusions in the brain. Since their main component is 
conformationally modified AS, aggregation of the latter is thought to be a key pathogenic 
event in these diseases. The analysis of inclusion body constituents gives additional 
information about pathways also involved in the pathology of synucleinopathies. 
Widespread mitochondrial dysfunction is very closely related to disease development. 
The impairment of protein degradation pathways, including both the ubiquitin-
proteasome system and the autophagy-lysosome
 pathway also play an important role 
during the development of Lewy body diseases. Finally, differential expression changes 
of isoforms corresponding to genes primarily involved in Lewy body formation point to 
alternative splicing as another important mechanism in the development of Parkinson’s 
disease, as well as dementia with Lewy bodies. The present paper attempts to give an 
overview of recent molecular findings related to the pathogenesis of Lewy body diseases. 
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Prologue 
 
Lewy body diseases (LBD) share alpha-synuclein (AS) aggregation and Lewy body (LB) formation 
as their key pathogenic events. The determination of the molecular pathways that lead to AS 
oligomerization and further aggregation is the basis for the successful design and development of 
treatments for important neurodegenerative diseases such as Parkinson’s disease (PD) and dementia 
with Lewy bodies (DLB). After an introduction of the various LBD, this review summarizes molecular 
findings over the last two years that provide new insight into the pathogenesis of LBD.  
 
1. Lewy body diseases 
 
LBD are characterized by the presence on intraneuronal proteinaceous inclusions called Lewy 
bodies (LBs) with AS as their main component. Whereas these are found mainly within the brainstem 
in the case of PD, their widespread distribution through almost all brain areas is a characteristic feature 
in DLB. Neuropathologically, the presence of LB is accompanied by neurodegeneration in the affected 
areas, therefore the brainstem affectation in PD causes parkinsonian symptoms and the additional 
cortical affectation in DLB, dementia.  
 
1.1. Parkinson’s Disease 
 
First described in 1817, PD is the most common progressive movement disorder in the elderly and 
is characterized by tremor, rigidity, and bradykinesia. There is increasing evidence that PD is a multi-
systemic disorder showing both progressive degeneration of the dopaminergic nigrostriatal system and 
widespread extranigral pathology [1-3]. In PD, LB pathology first appears in lower brainstem nuclei 
such as the dorsal motor nucleus of the vagus and the olfactory system (Stages 1-2). Afterwards, 
ascending progression leads to changes in the coeruleus complex, substantia nigra pars compacta, 
basal forebrain magnocellular nucleus, subthalamic nucleus, and amygdala (Stages 3-4). Finally, 
involvement of the neocortex may supervene (Stages 5-6) [1,2].  
Over the last few years advances in PD genetics have revealed that mutations are responsible for 
only a small proportion of cases, the majority being of sporadic origin. Of the six genes responsible for 
Mendelian forms of PD, the first identified was the AS (SNCA) gene, in which three pathogenic point 
mutations (A30P, E476K and A53T) as well as duplications and triplications have been detected [3-7]. 
Genes involved in PD genetics by mutations in autosomic dominant familial cases the ubiquitin C-
terminal hydrolase L1 (UCH-L1) gene [8], the dardarin gene, leucine-rich kinase 2 (LRRK 2) [9] and 
the HtrA2/Omi gene [10]. DJ-1 gene [11], PTEN-induced putative kinase 1 (PINK1) gene [12] and 
parkin (PRKN) gene mutations are responsible for autosomal recessive Parkinson cases  [13]. 
Interestingly, the vast majority of PD instances associated with PRKN mutations lack LBs [14]. 
Sporadic PD has been associated to mutations in the synphilin [8], LRRK 2 [9] and HtrA2/Omi [10] 
genes and to the S18Y polymorphism of the UCH-L1 gene that lowers the risk to suffer PD [15]. 
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1.2. Dementia with Lewy Bodies 
 
DLB is the second most frequent cause of dementia in the elderly after Alzheimer disease (AD) 
[16] and is clinically characterized by progressive dementia, often accompanied by parkinsonism and 
psychiatric symptoms [17]. Widespread distribution of LBs in virtually every brain area is a typical 
feature of DLB, although the frontal cortex, pigmented midbrain and brainstem nuclei, dorsal efferent 
nucleus of the vagus, basal forebrain nuclei, and limbic cortical regions are particularly involved [18].  
A high percentage of DLB cases show, in addition to LB related pathology, AD characteristic 
changes [19-21], where higher Braak stages of AD-type pathology result in a clinical diagnosis of AD 
rather than DLB [22]. Accordingly, the misdiagnosis of DLB increases with increasing Braak stages of 
AD associated pathology [23].  
Four mutations, the E46K mutation on SNCA [5], the UCH-L1 gene I93M mutation [8] and two 
beta-synuclein mutations (V70M and P123H) [24] have been described in four DLB pedigrees. In 
contrast, up to the present, no genetic marker has been found to be associated with sporadic DLB.  
 
2. Lewy Bodies 
 
Similar to other neurodegenerative disorders, increasing evidence suggests that the presence of 
compact inclusions may represent a protective mechanism on the part of surviving cells [25,26]. 
Whereas LBD are characterized by the general neuronal loss of the dopaminergic system, a high 
percentage of surviving neurons contain intracellular inclusions in the form of LB. These seem to 
protect the cell by the up-take of misfolded and un-functional proteins [27,28].  
  
2.1. Structure 
 
Morphologically, LBs may be divided into brainstem and cortical types. Whereas brainstem LBs 
are found in the brainstem nuclei and diencephalon, cortical LBs are preferentially seen in the cerebral 
limbic cortex and amygdala. Classic brainstem LBs are spherical intraneuronal cytoplasmic inclusions, 
characterized by hyaline eosinophilic cores, concentric lamellar bands, narrow pale halos, and 
immunoreactivity for AS and ubiquitin [29]. In contrast, cortical LBs
 typically lack a halo [30]. AS 
immunolabeling of PD brains have
 revealed that AS immunostaining can be detected in approximately 
64% of nigral LBs and 31% of cortical LBs [31]. 
  
2.2. Components 
 
Up to the present, a large number of proteins has been identified in LBs, but their precise 
biochemical composition has not yet been elucidated [32].  
The main component of inclusion bodies in synucleinopathies is AS and after its initial aggregation, 
additional proteins are captured and accumulated to the LB. More than 76 LB components have been 
described so far [33]. They belong to ten different protein classes, including structural elements, AS-
binding proteins, synphilin-1-binding proteins, components of the ubiquitin-proteasome system, Int. J. Mol. Sci. 2009, 10                 
   
727
proteins implicated in cellular responses, proteins associated with phosphorylation and signal 
transduction, cytoskelatal proteins, cell cycle proteins, cytosolic proteins and others [33].  
 
2.3. Formation 
 
AS aggregation is now accepted as the key step preceding LB formation. Although the precise 
sequence of events responsible for AS fibrillation remains unknown, advances in elucidating the 
course of AS aggregation have been attained. First, aggregated AS species with altered solubility as 
well as substantial accumulation of detergent-soluble and detergent-insoluble AS species of various 
molecular weights are found particularly in the grey matter [29]. As revealed by ultrastructural studies 
of AS filaments in LBs, pale bodies,
 and perikaryal threads, AS perikaryal threads are an early stage of
 
AS filament assembly [34]. Pale bodies occur after incorporation of p62 and assimilation of less 
aggregated forms of AS [30]. Afterwards, LB appearance would be coincidental with increasing 
ubiquitin immunoreactivity, due to further incorporation of mono- and di-ubiquitylated AS [35] and 
capture and [36] accumulation of additional proteins [36,37]. Final stages of LB formation are 
characterized by involvement of dendrites, LB distortion and finally by LB degradation showing loose 
filamentous components, decreased AS immunoreactivity, and astroglial process involvement [38]. 
  
3. Alpha-synuclein oligomerisation and aggregation – neurotoxicity vs. protection 
 
AS aggregation represents a key event in the pathogenesis of LBD. Therefore, AS structure, 
conformational behaviour and aggregatory properties have been extensively studied over the last years. 
Accumulated knowledge can be consulted in many review articles concerning this topic [39,40-45].  
AS aggregation is preceeded by its oligomerization. But in addition to oligomers that undergo fast 
transition to a fibrillary state, stable prefibrillar AS oligomers are also detected. These AS protofibrils 
constitute the deleterious species of the protein [46,47] and are toxic, causing cell death. Specifically, 
AS 67-82, 72-82 and 72-80 peptides, located within the central or NAC region, display in addition to 
their toxicity, beta-sheet secondary structure and aggregate forming fibrils [48-50]. Three possible 
mechanisms for AS neurotoxicity have been proposed. First, direct AS interaction with histones 
inhibiting their acetylation could cause nuclear AS neurotoxicity [51,52], second, AS protofibrils with 
pore-like activity or with pore-like structure, are able to permeabilize membranes, so disrupting ionic 
and metabolic homeostasis [45,53] and third, AS was shown to inhibit the function of the neuronal 
survival factor MEF2D causing about 40% loss of neuronal viability [54].  
In contrast, inclusion body formation does not necessarily lead to cell death, but seems to represent 
a protective mechanism of the cell for survival [25,26]. Nevertheless, it has not been excluded that AS 
aggregates per se or some event associated with the AS aggregation process are neurotoxic [55]. On 
one hand, cell and animal models of different neurodegenerative diseases develop inclusion bodies that 
conversely correlate with cell death [56], and synphilin-1 and synphilin-1A inclusion bodies can be 
cytoprotective in PD [8,25,57,58]. However, on the other hand, inclusions formed by 
monoubiquitylated AS increse cell death, and AS inclusions in Drosophila are neurotoxic [59]. 
Moreover, the fact that monoubiquitylated AS forms amorphous cytotoxic inclusions [35] and that 
LBs contain amourphous aggregated proteins in the core and fibrils in their periphery [60], imply that Int. J. Mol. Sci. 2009, 10                 
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LB may be toxic to cells at their initial stages of formation [35]. The further co-aggregation of 
additional PD-related proteins may counteract this toxicity that is possibly present at initial stages. 
Nevertheless, to date it is still impossible to predict how LB formation affects dopaminergic neuron 
viability in PD patients because of their complex protein composition [61]. 
    Ubiquitylation and phosphorylation of both AS and AS aggregation related proteins, are important 
mechanisms in the regulation of AS aggregation. Whereas about 10% of AS is monoubiquitilated in 
LBs [62,63], soluble AS is not [63]. Although AS monoubiquitylation rates are low within LBs, these 
could enhance AS aggregation and seed the formation of inclusion bodies [61].  
Parkin, UCH-L1 and PINK1 are also proteins found in LBs [33]. When ubiquitylated, all of them 
are able to form intracellular inclusions [64,65], indicating that ubiquitylation of different proteins 
involved in PD may contribute to LB formation [66]. 
Phosphorylation modulates the ubiquitylation and aggregational properties of various proteins [67]. 
In addition to being monoubiquitylated, AS is also phosphorylated at serin 129 in LBs [63,68]. 
Moreover, protein kinases, such as GSK3ß and Cdk5 modulate the death of dopaminergic neurons in 
pharmakological PD models [69,70]. Of these, Cdk5 phosphorylates parkin at serine 131, decreasing 
its ability to ubiquitylate synphilin-1 [71]. Parkin moreover decreases synphilin-1 and AS toxicities 
and promotes inclusion body formation [72]. 
Synphilin-1, an AS interacting protein, interacts with and is phosphorylated by the protein kinases 
GSK3ß and casein kinase II (CKII) [73,74]. Whereas GSK3ß decreases synphilin-1 ubiquitylation and 
inclusion body formation [74], CKII increases inclusion body formation regardless of synphilin-1 
ubiquitylation [73,74]. 
The exhaustive analysis of LB components in dependence on the disease stage may give 
information about the dysfunction of the various pathways involved in LB disease development.  
It is worth mentioning that in addition to AS, all other proteins linked to PD or DLB by disease 
causing mutations, are also found in LBs. Of these, PINK1, parkin, DJ-1 and HtrA2/Omi are 
mitochondria related genes, UCH-L1 and also parkin proteasome related proteins, and synphilin-1 has 
been related to proteosomal dysfunction by its ablity to interact with various proteosomal proteins. 
Beta-synuclein is an exception, because although mutated in DLB it is not found in LBs, probabely 
because of its AS- antiaggregatory properties.  
  
4. Mitochondrial dysfunction  
  
Mitochondrial dysfunction, in part thought to be responsible for oxidative stress, is an important 
factor involved in the preferential cell loss seen for some groups of neurons in the brain [75]. 
Accordingly, some of the genes that cause recessive parkinsonism are associated, directly or indirectly, 
with mitochondrial function [76-78]. Although recessive parkinsonism differs phenotypically from 
LBD, in addition to the common feature of prominent nigral cell loss, an important role of 
mitochondrial dysfunction also in LBD has been suggested. Two of such PD and mitochondrial 
function related proteins are parkin and PTEN-induced kinase 1 (PINK1) [79,80]. 
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4.1. Parkin 
  
Parkin is an ubiquitin E3 ligase that contains a ubiquitin like domain, two ring finger domains and 
between the ringfinger domains, a conserved region [81]. As ubiquitin E3 ligase, parkin has been 
related to the proteasome, but it has not been excluded that this activity can be proteasome   
independent [80].  
 Parkin loss-of-function Drosophila models exhibit dramatic defects of mitochondrial morphology 
[82,83] and parkin knockout mice show signs of oxidative tissue damage in the brain [84]. Although 
initially several fly and mouse models have located parkin partially in the outer mitochondrial 
membrane, at steady state it is primarily cystosolic [84-86] and it participates in the regulation of 
mitochondrial function [84,85].  
Together with PINK1 parkin constitutes the Pink1/parkin pathway that promotes mitochondrial 
fission [87,88]. PINK1 could act through a signal transduction cascade promoting parkin dependent 
ubiquitylation of particular cytoplasmic targets related to mitochondrial morphogenesis [87]. 
Moreover, parkin is strikingly and specifically recruited to dysfunctional mitochondria, where it 
regulates their selective removal by autophagy [86,89].  
  
4.2. PINK-1 
 
The PTEN-induced putative kinase, PINK1 localizes predominantly within mitochondria, 
specifically at the inner mitochondrial membrane [90,91].  
PINK-1 loss-of-function Drosophila presents reduced ATP levels as well as mitochondrial DNA 
content [77,78,92] and mitochondria within dopaminergic neurons present an altered morphology [78]. 
Since parkin overexpression in flies suppresses all PINK1 mutant phenotypes, but PINK1 
overexpression does not compensate for loss of parkin function [77,78,92], PINK1 and parkin seem to 
act in a linear pathway that affects mitochondrial function with parkin downstream to PINK1 [80]. In 
peripheral tissues from PD patients with PINK1 [93] and parkin [94] mutations, as well as with 
sporadic PD [95] have been detected pathological changes and defects in mitochondrial respiration. 
Furthermore, PINK1 directly phosphorylates parkin [96] but also the mitochondrial serin protease 
Omi/HtrA2 [97]. Phosphorylation of parkin induces its translocation to mitochondria so that PINK1 
mutations could cause PD by decreased PINK1 kinase activity that at the same time would lead to low 
parkin levels within mitochondria [96].  
 
4.3. Omi/HtrA2 
 
Omi/HtrA2 contributes to the progression of apoptosis [77,78,98,99]. It is released from the 
mitochondrial intermembrane space into the cytosol, where it induces apoptotic cell death in addition 
to the permeabilization of the mitochondrial membrane that at the same time leads to cytochrome c 
release [98-100]. 
Although Omi/HtrA2 is phosphorylated in a PINK1-dependent manner [97], the functional 
importance of this interaction remains to be elucidated. However, both PINK1 and Omi/HtrA2 interact 
and Omi/HtrA2 functions downstream of Pink1 [101]. Surprisingly, there is no evidence of interaction Int. J. Mol. Sci. 2009, 10                 
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between Omi/HtrA2 and parkin, and both act as independent downstream effectors of PINK1. 
Although emerging evidence indicates that the PINK1/Parkin pathway is likely to affect mitochondrial 
dynamics, the function of the PINK1/Omi/HtrA2 pathway is currently unclear [101]. 
  Similar to parkin and PINK1, both the Omi/HtrA2 S399 mutant and the Omi/HtrA2 A141S 
polymorphism, induce mitochondrial dysfunction associated with altered mitochondrial   
morphology [102].  
  
5. Dysfunction of protein degradation pathways 
 
The ubiquitin-proteasome system (UPS) and autophagy-lysosome
 pathway (ALP) are the two most 
important mechanisms that normally
 repair or remove abnormal proteins from the cell. Alterations in 
the function
 of these systems to degrade misfolded and aggregated proteins
 are being increasingly 
recognized to play a fundamental role
 in the pathogenesis of many neurodegenerative disorders. 
If AS degradation depends on the UPS or ALP remains unknown, but both seem to be involved in 
this process [103]. The recent finding that the inhibition of autophagy leads to the accumulation of 
monoubiquitilated AS forms followed by its aggregation [61], indicates that autophagy could be the 
predominant pathway involved in AS clearance [35,61].  
 
5.1. Proteasomal dysfunction 
 
The first indication for UPS dysfunction in diseased neurons was the detection of ubiquitylated 
proteins in proteinaceous inclusions found in neurodegenerative diseases [104]. Now it is known that 
polyubiquitylation is the canonical signal for targeting proteins to the proteasome for degradation [67]. 
Monoubiquitilation, on the contrary, regulates different cellular functions such as protein sorting in the 
late endosomal pathway, histone function and DNA repair [105].  
The involvement of the UPS dysfunction in PD was further underlined by the finding of decreased 
proteasome activity in sustancia nigra of PD brains [106]. Parkin, not only involved in mitochondrial 
function and dysfunction, is together with UCH-L1, a component of the UPS. Some familial PD forms 
are caused by mutations in their genes [107], and whereas parkin polyubiquitilates a rare glycosylated 
AS form [108], UCH-L1 polyubiquilates AS in vitro [109]. 
 
5.1.1. UCH-L1 
 
Linked to the UPS, the ubiquitin C-terminal hydrolase UCH-L1 is an abundant neuronal protein 
that moreover stabilizes free ubiquitin [110]. A missense mutation, I93M, has been detected in a 
German family with PD [107], and the S18Y polymorphism was found to be protective against PD in 
different populations [111,112]. Whereas the I93M mutant decreases UCH-L1 hydrolase activity by 
50% [107], the protective S18Y variant results in a slight increase of hydrolase activity [113].  
Moreover, it has been recently shown that the UCH-L1 S18Y variant acts as a potent antioxidant 
[110], protecting cells from induced oxidative damage in different cell models [110]. Its 
overexpression leads to protein aggregation, but not to apoptosis [110]. 
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5.1.2. SIAH-1 
 
 SIAH-1, along with parkin and UCH-L1, belongs to the UPS and is also an E3 ubiquitin ligase that 
has been detected in LB of PD patients [57]. SIAH-1 regulates the ubiquitilation and degradation of 
synaptophysin [114] and its interaction with synphilin-1 [57,58,71] is followed by synphilin-1 
polyubiquitylation and proteosomal degradation [115]. 
Furthemore, SIAH-1 seems to play a critical role in the regulation of AS aggregation and toxicity 
[66]. In contrast to polyubiquitylation of synaptophysin and synphilin-1, SIAH-1 interacts with and 
mono- and di-ubiquitylates AS [55,61]. AS purified from LB is ubiquitylated at lysines 12, 21, and  
23 [63].  
 
5.1.3. Synphilin-1 
 
Synphilin-1 was originally identified as an AS interacting protein [116] and its co-expression with 
AS in cell cultures leads to the formation of LB-like inclusions [73,116,117].  
Even if synphilin-1 is not located within the UPS, it is able to interact with various UPS related 
proteins. As a 919 amino acid protein, synphilin-1 contains different domains such as ankyrin-like 
repeats, a coiled-coil domain and a putative ATP,GTP-binding domain [116]. Moreover, synphilin-1 
localizes in the presynapse where it binds to synaptic vesicles [117] and may affect dopamine   
release [115].  
The first evidence that synphilin-1 interferes with the proteosomal function was that synphilin-1 
overexpression decreases of the reporter protein (GFPu) degradation, a protein normally highly 
degraded by the proteasome [74]. In addition, synphilin-1 interacts with two proteasome 
subunits/regulators, S6 ATPase (tbp7) and NUB1 [66]. Its interaction with S6 decreases proteasome 
function on one hand and co-expression of synphilin-1 and the S6 subunit increases the formation of 
aggresome-like intracytoplasmic inclusions, on the other [118]. Both not only co-localize in these 
inclusions, but also in LBs in PD [118]. 
Finally, synphilin-1 interacts with three E3 ubiquitin ligases: parkin, SIAH, dorfin. Whereas both 
parkin and SIAH ubiquitylate synphilin-1, followed by inclusions body formation, non-ubiquitylated 
synphilin-1 is not able to form inclusions [57,74,117,119].  
Because of its main characteristic to interact with multiple proteins and many of these are directly 
related to LB diseases, it has been proposed that synphilin-1 may assemble these proteins into a multi-
protein complex [66]. Accordingly it is located within the core of brainstem LB, but is also detected in 
cortical LB [33].  
  
5.2. Dysfunction of the autophagy-lysosomal pathway 
 
ALP comprises three distinct pathways based on
 the ways substrates reach the lysosomal lumen: 
macroautophagy, or autophagy, microautophagy and chaperone-mediated
 autophagy (CMA) [120]. Of 
these, CMA selectively degrades cytosolic proteins [121]. In contrast to the UPS, autophagy seems to 
be the primary mechanism involved
 in the degradation of long-lived, stable proteins. Moreover, it is Int. J. Mol. Sci. 2009, 10                 
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the
 only mechanism by which entire organelles such as mitochondria and large membrane proteins and 
protein complexes are recycled [120,122]. 
Evidence for the involvement of lysosomal dysfunction in LBD has been obtained during the last 
years. Deficiency of the lysosomal enzyme cathepsin D leads to the accumulation of endogenous AS in 
neurons without the overabundance of its mRNA. Conversely, cathepsin D overexpression reduces AS 
aggregation and shows a neuroprotective effect against AS overexpression-induced cell death in vitro 
[123].  Moreover, wild-type AS, but
 not mutant AS, is selectively translocated into
 lysosomes for 
degradation by the CMA pathway [120]. Mutant AS show a very increased affinity to lysosomal 
membrane receptors, a fact that could explain the failure of CMA to clear it [120]. 
Finally, very recently, lysosomal dysfunction has been directly related to AS overexpression and 
accumulation. A study on the regulation of the myocyte enhancer factor 2D (MEF2D), a neuronal 
survival factor, revealed that AS disrupts MEF2D CMA-mediated degradation [54]. MEF2D, normally 
located within the neuronal nucleus [121], translocates to the cytoplasm where it is degraded by the 
lysosomal system [54]. Overexpression of both wild type and mutated AS, inhibits the uptake of 
MEF2D by lysosomes and its degradation.  
 
6. Alternative splicing 
 
Alternative splicing is a versatile and widespread mechanism for the generation of multiple mRNAs 
from a single transcript. It leads to significant changes in protein secondary structure and these 
modifications may cause functional alterations by the specific deletion of functional protein domains. 
In the last few years an increasing number of genes involved in neurodegenerative disorders have been 
shown to express more than one splice variant differentially.  
Examples include the presenilin (PS) genes (PS1 and PS2), both of which undergo alternative 
splicing. Of the PS1 isoforms, one lacks exon 9 and the other two variably incorporate four amino 
acids (VRSQ) on exon 4 [124]. The four amino acid VRSQ-lacking isoform binds to the RabGDP 
dissociation inhibitor (rabGDI), whereas the VRSQ-containing isoform does not, a finding that 
constitutes the first evidence of a specific function for the different isoforms [125]. On the other hand, 
one of PS2 transcript variants lacks exon 5, resulting in a short, truncated protein which is 
differentially overexpressed in AD [126].  
Another alternatively spliced gene is tau, of which six isoforms resulting from complex splicing 
events are expressed in the adult brain [127-129]. The inclusion of exon 10, which codes for an 
additional microtubule-binding domain, causes frontotemporal dementia with parkinsonism [130]. 
Finally, it has been recently shown that differential expression of parkin and synphilin transcript 
variants is altered in LBDs [57,131]. 
 
6.1. AS alternative splicing  
 
Thus, four AS isoforms that result from alternative splicing have been described [39,132]. In 
addition to AS 140, representing the whole and major transcript of the protein [132-134], three other 
isoforms also exist: AS 126, AS 112 and AS 98. Whereas inframe deletions of exons 3 or 5 give rise to 
AS 126 and AS 112, respectively [133,134], the deletion of both exons 3 and 5 is found in AS 98 Int. J. Mol. Sci. 2009, 10                 
   
733
[132]. Exon 3 encodes for residues 41–54 within the N-terminus and its deletion results in the 
interruption of the four amphipathic α-helices of the membrane-binding domain. In contrast, exon 5 
encodes for residues 103–130 within the C-terminus, and its splice out shortens the unstructured AS 
part. Finally, AS 98 mainly preserves the central region of the protein intact. These structural changes 
resulting from alternative splicing of AS RNA strongly indicate functional changes of the shortened 
protein isoforms [132,135,136].  
 
6.1.1. AS 126 
 
AS 126 could represent an AS isoform with diminished aggregation properties due to the 
interruption of the membrane binding domain thought to be necessary during the first steps of AS 
aggregation [137]. In this context, we have shown that a polymorphic polyT site located in intron 2, 
co-regulates AS 126 expression levels in the brain and that high-AS 126-expression genotypes 
accumulate with aging in normal controls [138]. Additionally, AS 126 mRNA levels are drastically 
decreased in LBD frontal cortices in comparison with controls [135]. Both findings suggest that 
AS126 plays a protective role in the aging brain.  
 
6.1.2. AS112  
 
On the contrary, AS 112, that shows the shortening of the unorganized AS C-terminal, could be 
characterized by increased aggregation properties. Accordingly, isoform expression profiles obtained 
in frontal cortices of LB diseases revealed AS 112 overexpression, specifically in DLB [139].  
Interestingly, initial perikaryal AS accumulation seems to be specifically constituted by AS112 
[39,139]. AS112 lacks part of the unfolded protein C-terminal but conserves intact membrane-protein 
and protein-protein binding domains. Therefore, AS112 appears to be an aggregation-prone isoform 
with enhanced membrane-binding properties [39,139]. Additionally, the fact that aggregation of AS is 
preceded by its interaction with membranes [137] and that the small fraction of membrane-bound AS 
seeds the accumulation of the far more abundant cytosolic form [140], point to the AS112 membrane-
protein interaction domain as a crucial element in early aggregation steps [39]. 
 
6.1.3. AS98 
 
Finally, since AS 98 preserves mainly an unchanged central region that contains aggregation-prone 
(amino acids 71-82) and toxic (amino acids 67-82, 72-82) sequences [48-50,141], it could be the most 
amyloidogenic and toxic AS isoform. Accordingly, AS 98 mRNA is overexpressed in LBD as well as 
Alzheimer disease [132].  
 
6.2. Synphilin-1 alternative splicing 
 
In addition to the differential expression of AS isoforms, alternative splicing of other genes with an 
important involvement in LBD pathogenesis seems also to be affected. Of these, synphilin-1 bears 8 
isoforms as result of alternative splicing. Int. J. Mol. Sci. 2009, 10                 
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As a major AS interaction protein on one hand [116] and as a parkin substrate on the other 
[117,119,142], the main functional synphilin-1 domains are responsible for the interaction with them. 
They are variably shortened in the transcript variants synphilin-1A, 1B and 1C. The four shortest 
isoforms correspond to truncated, probably unfuntional proteins.  
 
6.2.1. Synphilin-1A  
 
Synphilin-1A is an unusual splice variant of synphilin-1 [58]. It is characterized by a different start 
codon leading at the same time to a different initial reading frame. Moreover, synphilin-1A lacks the 
first 394 amino acids and contains additional, very protein specific, amino acid streches, one at the N- 
and the other on the C-terminus [58].  
Synphilin-1A is an aggregation-prone and neurotoxic protein but forms nevertheless 
neuroprotective inclusions. Moreover, that synphilin-1A interacts with synphilin-1 as well as AS and 
localizes in LBs, suggesting that synphilin-1A performs its own, isoform-specific function [117,143]. 
In this context, synphilin-1A’s early involvement during LBD pathogenesis could be confirmed by our 
finding of synphilin-1A overexpression in PD together with its normal levels in pDLB [136]. 
Due to its intrinsic neurotoxicity, interaction changes between synphilin-1A and AS could be 
involved not only in in LB formation but also in dopaminergic neuronal death [66]. 
 
6.3. Parkin alternative splicing 
 
So far, 7 different transcript variants (TV) of parkin have been identified. Parkin as one of E3-
ubiquitin ligases [124], contains an ubiquitin-like as well as a ring-finger domain, both involved in 
ubiquitylation of a specific substrate. Parkin isoforms TV2 and TV3 show a shortened sequence 
between functional domains [144], possibly leading to changes in the efficiency of substrate 
recognition or ubiquitylation. 
As a possible result, the shortened isoforms of synphilin-1 and parkin could present stronger 
interactions than normal-length proteins. The non-dissociation of synphilin-1 – parkin or synphilin-1 – 
AS complexes could play an important role during the protein aggregation that precedes LB formation. 
SNCA and synphilin-1 overexpression in PD frontal cortex, a region not yet affected by LB pathology, 
underlines this idea, and is further supported by the finding that synphilin-1 and parkin are early 
components of LBs [119,143]. 
 
6.4. Isoform expression profiles  
 
Recently, we have obtaind isoform exression profiles composed by the 4 AS, 4 synphilin-1 and 7 
parkin isoforms [136]. We have shown that the different LB diseases present their own isoform 
expression profiles in frontal cortex. Changes in protein-protein interactions resulting from the lack or 
overrepresentation of some of the isoforms could be responsible for diminution or gain of function. 
Since both parkin and synphilin-1 are involved in the proteasome mediated protein degradation, and an 
important proteasome dysfunction can be observed in synucleinopathies, one of the mechanisms 
leading to such a dysfunction could be the alteration of alternative splicing.  Int. J. Mol. Sci. 2009, 10                 
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Moreover, the results strongly support the idea that the different LBD are characterized by their 
own molecular mechanisms of disease development. Furthermore, our data strengthen the hypothesis 
that different molecular mechanisms lead to the development of similar neuropathological changes. 
Elucidating these different mechanisms, as well as ascertaining the clinical diagnosis of LB diseases, 
will help in the development of appropriate and efficient treatments for each of them. 
 
Conclusions 
 
A main characteristic of LBD, similar to other neurodegenerative conditions, is their genetic 
heterogeneity. Whereas multiple forms of familial PD are caused by mutations in at least seven 
different genes, sporadic cases that represent the majority of all LBD do not show a defined genetic 
profile. This observation, in addition to the alteration of multiple pathways during disease 
development, suggests the existence of more than one subtype of each disease where similar 
neuropathological changes are the result of different primary molecular mechanisms.  
All patients with clinical diagnosis of PD or DLB, present LBs when analyzed in a post-mortem, 
neuropathologic study. The only exception are juvenile PD cases caused by mutations in the parkin 
gene. In contrast, LBs are also found in a relative high percentage of asymptomatic individuals 
[145,146]. These observations strongly indicate that some individuals are provided by protective 
mechanisms against LBD, but that LBs and their formation process are closely related to disease 
development. Although the sequence of brain area affectation is now well-known, neither the earliest 
mechanisms responsible for AS aggregation nor their chronological order have been determined. 
Indeed, the exact sequence of pathological alterations that finally lead to disease development remains 
unknown. Taken together these observations, it would seem that efficient treatments will differ in all 
PD and DLB groups, or even in patients. 
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